NCT04552535View on ClinicalTrials.gov

A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

May 8, 2020

Primary Completion Date

May 18, 2020

Study Completion Date

May 18, 2020

Conditions
Squamous Non-small Cell Lung Cancer
Interventions
DRUG

Second line (2L) afatinib

Afatinib

DRUG

Second line chemotherapy

Chemotherapy

Trial Locations (1)

43017

Cardinal Health Specialty Solutions, Dublin

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04552535 - A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung | Biotech Hunter | Biotech Hunter